{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Platelet+Coagulation+Disorders&page=8",
    "query": {
      "condition": "Platelet Coagulation Disorders",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 373,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Platelet+Coagulation+Disorders&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Platelet+Coagulation+Disorders&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T01:21:46.358Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06665308",
      "title": "Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Immune Thrombocytopenia",
        "Primary Immune Thrombocytopenia",
        "Adult Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2025-01-13",
      "completion_date": "2025-11-26",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Seattle, Washington",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06665308"
    },
    {
      "nct_id": "NCT05885555",
      "title": "A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "Ianalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 41,
      "start_date": "2023-08-16",
      "completion_date": "2029-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05885555"
    },
    {
      "nct_id": "NCT07362225",
      "title": "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycythemia Vera",
        "ET (Essential Thrombocythemia)",
        "Polycythemia Vera (PV)",
        "Essential Thrombocythemia (ET)",
        "Primary Myelofibrosis (MF)",
        "Primary Myelofibrosis (PMF)",
        "Myelofibrosis",
        "Myelofibrosis (MF)",
        "Myelofibrosis, Primary",
        "Myelofibrosis, Post ET",
        "Myelofibrosis, Post PV",
        "Myelofibrosis (PMF)",
        "Myelofibrosis，MF",
        "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis",
        "Myelofibrosis Due to and Following Polycythemia Vera",
        "Myelofibrosis Transformation in Essential Thrombocythemia",
        "Myelofibrosis With High Molecular Risk Mutations",
        "MF",
        "Secondary Myelofibrosis",
        "Secondary Myelofibrosis in Myeloproliferative Disease",
        "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)",
        "Post-Polycythemia Vera Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis (PPV-MF)",
        "Post-polycythemia Vera Myelofibrosis (Post-PV MF)",
        "Post-polycythemia Vera Myelofibrosis(Post-PV MF)",
        "Post-PV MF",
        "Post-Essential Thrombocythemia Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis (PET-MF)",
        "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)",
        "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)",
        "Post-ET MF",
        "Pre-fibrotic Myelofibrosis",
        "Myeloproliferative Disorder",
        "Myeloproliferative Disorders",
        "Myeloproliferative Disorders (MPD)",
        "Myeloproliferative Neoplasms (MPNs)",
        "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis",
        "Myeloproliferative Neoplasm With 10% Blasts or Higher",
        "Myeloproliferative Neoplasms",
        "MPN",
        "MPN (Myeloproliferative Neoplasms)",
        "MPN-associated Myelofibrosis",
        "Myeloproliferative Neoplasm, Unclassifiable",
        "Myeloproliferative Neoplasm, Not Otherwise Specified",
        "Accelerated Phase MPN",
        "Accelerated Phase Myeloproliferative Neoplasm",
        "Blast Phase MPN",
        "Blast Phase Myeloproliferative Neoplasm",
        "Thrombocythemia Myelofibrosis (PET-MF)",
        "Thrombocythemia, Essential",
        "Thrombocythemia, Hemorrhagic",
        "Agnogenic Myeloid Metaplasia",
        "Chronic Idiopathic Myelofibrosis",
        "Idiopathic Myelofibrosis",
        "MDS/MPN Crossover Syndromes"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "MPN Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2025-09-26",
      "completion_date": "2035-09-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07362225"
    },
    {
      "nct_id": "NCT00002980",
      "title": "Decitabine in Treating Patients With Melanoma or Other Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Precancerous Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Cancer Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1997-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-15",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002980"
    },
    {
      "nct_id": "NCT06754852",
      "title": "A Study Assessing HMB-002 in Participants With Von Willebrand Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Von Willebrand Disease (VWD)",
        "Von Willebrand Disease (VWD), Type 1",
        "Von Willebrand Disease (VWD), Type 2",
        "Von Willebrand Disease (VWD), Type 3"
      ],
      "interventions": [
        {
          "name": "HMB-002 (Part A)",
          "type": "DRUG"
        },
        {
          "name": "HMB-002 (Part B)",
          "type": "DRUG"
        },
        {
          "name": "HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hemab ApS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "16 Years to 69 Years"
      },
      "enrollment_count": 108,
      "start_date": "2025-02-06",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06754852"
    },
    {
      "nct_id": "NCT00054340",
      "title": "Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Graft Versus Host Disease",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "2002-10",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2010-05-14",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054340"
    },
    {
      "nct_id": "NCT03275740",
      "title": "A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Primary Immune Thrombocytopenia",
        "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
      ],
      "interventions": [
        {
          "name": "PF-06755347 intravenous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "Placebo intravenous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "PF-06755347 subcutaneous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "Placebo subcutaneous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "PF-06755347 subcutaneous ITP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 58,
      "start_date": "2017-07-17",
      "completion_date": "2023-01-06",
      "has_results": true,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03275740"
    },
    {
      "nct_id": "NCT00359463",
      "title": "Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Purpura, Thrombocytopaenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "eltrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2006-04-18",
      "completion_date": "2007-03-07",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00359463"
    },
    {
      "nct_id": "NCT01164163",
      "title": "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ruxolitinib phosphate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 49,
      "start_date": "2010-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-10-23",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01164163"
    },
    {
      "nct_id": "NCT00397813",
      "title": "Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Chronic Myelomonocytic Leukemia",
        "de Novo Myelodysplastic Syndrome",
        "Essential Thrombocythemia",
        "Myeloproliferative Neoplasm",
        "Paroxysmal Nocturnal Hemoglobinuria",
        "Polycythemia Vera",
        "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
        "Primary Myelofibrosis",
        "Refractory Anemia",
        "Refractory Anemia With Excess Blasts",
        "Refractory Anemia With Ring Sideroblasts",
        "Refractory Cytopenia With Multilineage Dysplasia",
        "Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts"
      ],
      "interventions": [
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 77,
      "start_date": "2006-01",
      "completion_date": "2018-03",
      "has_results": true,
      "last_update_posted_date": "2020-01-31",
      "last_synced_at": "2026-11-19T01:21:46.358Z",
      "location_count": 3,
      "location_summary": "Salt Lake City, Utah • Seattle, Washington",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00397813"
    }
  ]
}